Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Integra Lifesciences Holdings (IART) Interest Expenses (2016 - 2025)

Integra Lifesciences Holdings' Interest Expenses history spans 17 years, with the latest figure at $23.7 million for Q4 2025.

  • For Q4 2025, Interest Expenses rose 24.7% year-over-year to $23.7 million; the TTM value through Dec 2025 reached $86.3 million, up 22.12%, while the annual FY2025 figure was $86.3 million, 22.12% up from the prior year.
  • Interest Expenses for Q4 2025 was $23.7 million at Integra Lifesciences Holdings, up from $22.7 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $23.7 million in Q4 2025 and bottomed at $12.1 million in Q1 2023.
  • The 5-year median for Interest Expenses is $13.4 million (2021), against an average of $15.8 million.
  • The largest annual shift saw Interest Expenses plummeted 41.37% in 2021 before it surged 49.64% in 2024.
  • A 5-year view of Interest Expenses shows it stood at $12.1 million in 2021, then rose by 5.64% to $12.8 million in 2022, then increased by 7.35% to $13.8 million in 2023, then soared by 38.06% to $19.0 million in 2024, then rose by 24.7% to $23.7 million in 2025.
  • Per Business Quant, the three most recent readings for IART's Interest Expenses are $23.7 million (Q4 2025), $22.7 million (Q3 2025), and $21.0 million (Q2 2025).